Piper Sandler Reiterates Overweight on Corcept Therapeutics, Maintains $35 Price Target
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst David Amsellem has reiterated an Overweight rating on Corcept Therapeutics (NASDAQ:CORT) and maintained a $35 price target.
July 01, 2024 | 1:44 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler analyst David Amsellem has reiterated an Overweight rating on Corcept Therapeutics and maintained a $35 price target.
The reiteration of an Overweight rating and the maintenance of a $35 price target by a reputable analyst can boost investor confidence in Corcept Therapeutics, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100